{"id":"rifampin-iv","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Discoloration of body fluids (orange-red)"},{"rate":null,"effect":"Drug interactions (enzyme induction)"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL374478","moleculeType":"Small molecule","molecularWeight":"822.95"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rifampin binds to the bacterial RNA polymerase enzyme and inhibits RNA synthesis by blocking the path of elongating RNA transcripts. This mechanism is selective for bacterial RNA polymerase and does not significantly affect eukaryotic RNA polymerases, making it effective as an antibiotic. The drug is bactericidal and has broad-spectrum activity against many gram-positive and gram-negative bacteria, as well as mycobacteria.","oneSentence":"Rifampin inhibits bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:01.210Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (pulmonary and extrapulmonary)"},{"name":"Mycobacterium avium complex (MAC) infection"},{"name":"Leprosy"},{"name":"Endocarditis (as adjunctive therapy)"},{"name":"Atypical mycobacterial infections"}]},"trialDetails":[{"nctId":"NCT06889701","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants","status":"RECRUITING","sponsor":"TenNor Therapeutics Inc.","startDate":"2025-04-03","conditions":"Periprosthetic Joint Infection (PJI)","enrollment":33},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360},{"nctId":"NCT02701608","phase":"PHASE3","title":"Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2016-02-29","conditions":"Infective Endocarditis","enrollment":162},{"nctId":"NCT05074147","phase":"PHASE3","title":"Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2)","status":"WITHDRAWN","sponsor":"Tourcoing Hospital","startDate":"2022-05-01","conditions":"Osteomyelitis - Foot","enrollment":""},{"nctId":"NCT07332325","phase":"PHASE3","title":"STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2026-04","conditions":"Sepsis, Tuberculosis","enrollment":344},{"nctId":"NCT03915366","phase":"PHASE2, PHASE3","title":"Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia","status":"COMPLETED","sponsor":"Hospital Universitario 12 de Octubre","startDate":"2020-03-01","conditions":"Pneumonia, HIV/AIDS, Tuberculosis","enrollment":563},{"nctId":"NCT07148960","phase":"PHASE4","title":"Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?","status":"ENROLLING_BY_INVITATION","sponsor":"West Virginia University","startDate":"2025-09-15","conditions":"Staphylococcus Aureus Bacteremia","enrollment":300},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT05821478","phase":"PHASE3","title":"Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients","status":"RECRUITING","sponsor":"Institut Pasteur","startDate":"2025-05-22","conditions":"Hidradenitis Suppurativa","enrollment":92},{"nctId":"NCT04166669","phase":"PHASE1","title":"A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001","status":"COMPLETED","sponsor":"Basilea Pharmaceutica","startDate":"2019-11-12","conditions":"Fungal Infection","enrollment":36},{"nctId":"NCT05156437","phase":"PHASE4","title":"Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)","status":"ENROLLING_BY_INVITATION","sponsor":"Vinay Badhwar","startDate":"2022-03-16","conditions":"Endocarditis","enrollment":20},{"nctId":"NCT05896930","phase":"PHASE2","title":"Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"TASK Applied Science","startDate":"2017-11-09","conditions":"Pulmonary Tuberculosis","enrollment":134},{"nctId":"NCT04629378","phase":"PHASE2","title":"Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB","status":"COMPLETED","sponsor":"TASK Applied Science","startDate":"2020-08-17","conditions":"Tuberculosis","enrollment":22},{"nctId":"NCT04029584","phase":"PHASE4","title":"Drug-Drug Interaction Between Rifampin and Fluvastatin","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2019-04-25","conditions":"Drug-drug Interaction","enrollment":10},{"nctId":"NCT01561963","phase":"PHASE1","title":"A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-02-01","conditions":"Healthy Subjects","enrollment":21},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT02106767","phase":"PHASE1","title":"The Effects of Rifampin on the Pharmacokinetics of Rosuvastatin","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2014-11","conditions":"Healthy","enrollment":16},{"nctId":"NCT01576575","phase":"NA","title":"Buprenorphine Disposition and CYP3A","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2010-06","conditions":"Healthy","enrollment":21},{"nctId":"NCT00816426","phase":"PHASE1","title":"Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-12-29","conditions":"Tuberculosis","enrollment":19},{"nctId":"NCT01756924","phase":"PHASE2","title":"Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection","status":"TERMINATED","sponsor":"Arrevus Inc.","startDate":"2012-12","conditions":"Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Infected Spacers","enrollment":14},{"nctId":"NCT03801746","phase":"PHASE1","title":"Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2018-07-20","conditions":"Drug Interaction Potentiation","enrollment":40},{"nctId":"NCT02901288","phase":"PHASE4","title":"Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2016-08","conditions":"Tuberculosis, Pulmonary","enrollment":3900},{"nctId":"NCT03002493","phase":"PHASE1","title":"To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Eisai Limited","startDate":"2009-12","conditions":"Tumor","enrollment":14},{"nctId":"NCT02097953","phase":"EARLY_PHASE1","title":"Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-05","conditions":"Drug Interactions, Pharmacokinetics","enrollment":12},{"nctId":"NCT02328443","phase":"PHASE1","title":"Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of DDI","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT00534807","phase":"PHASE1","title":"A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2007-09","conditions":"Cancer","enrollment":""},{"nctId":"NCT02443064","phase":"PHASE4","title":"Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2014-01","conditions":"Blood Stream Infections, Endocarditis, MRSA","enrollment":100},{"nctId":"NCT02121314","phase":"PHASE2","title":"HRZE Fasted/Fed in Newly Diagnosed TB","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2013-07","conditions":"Tuberculosis","enrollment":20},{"nctId":"NCT00935363","phase":"PHASE1","title":"Interplay Between Organic Anion Transporting Polypeptide (OATP) Transporters Transporters and CYP2C9 in Glyburide Pharmacokinetics (PK)","status":"WITHDRAWN","sponsor":"University of California, San Francisco","startDate":"2010-02","conditions":"Healthy","enrollment":""},{"nctId":"NCT01218620","phase":"PHASE1","title":"Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-09","conditions":"Adult Solid Neoplasm","enrollment":17},{"nctId":"NCT01026415","phase":"PHASE1","title":"Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)","status":"COMPLETED","sponsor":"Seagen Inc.","startDate":"2009-12","conditions":"Carcinomas, Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic","enrollment":73},{"nctId":"NCT00711854","phase":"PHASE4","title":"Randomized Clinical Trial to Compare a Regimen of Trimethoprim-sulfamethoxazole Plus Rifampicin With a Regimen of Linezolid in the Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2009-01","conditions":"MRSA Infection","enrollment":150},{"nctId":"NCT01757236","phase":"PHASE2","title":"Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection","status":"UNKNOWN","sponsor":"University Hospital, Tours","startDate":"2012-10","conditions":"Hip Prosthetic Joint Infection","enrollment":100},{"nctId":"NCT01760642","phase":"PHASE1","title":"Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2012-12","conditions":"Healthy","enrollment":16},{"nctId":"NCT02123628","phase":"PHASE4","title":"Antibiotic Treatment Duration for Non-Surgically-Treated Diabetic Foot Osteomyelitis","status":"COMPLETED","sponsor":"Tourcoing Hospital","startDate":"2007-06","conditions":"Diabetes Mellitus","enrollment":40},{"nctId":"NCT00777855","phase":"NA","title":"Drug Interaction Study of Rifampin and Warfarin in Healthy Volunteers.","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-11","conditions":"Healthy","enrollment":10},{"nctId":"NCT00423982","phase":"PHASE4","title":"Rifampin Combination Therapy Versus Monotherapy in Early Staphylococcal Infections After Total Hip and Knee Arthroplasty","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2006-04","conditions":"Prosthesis-related Infections, Staphylococcal Infections","enrollment":100},{"nctId":"NCT01215214","phase":"PHASE1","title":"Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity Using Metabolomics","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2010-10","conditions":"Healthy","enrollment":24},{"nctId":"NCT00548002","phase":"","title":"Combination Therapy With Fluoroquinolone in Staphylococcus Aureus Bacteremia","status":"COMPLETED","sponsor":"University of Helsinki","startDate":"1999-01","conditions":"Staphylococcus Aureus, Bacteremia, Endocarditis","enrollment":430}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":282,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RIFADIN™"],"phase":"marketed","status":"active","brandName":"rifampin IV","genericName":"rifampin IV","companyName":"University of California, San Francisco","companyId":"university-of-california-san-francisco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifampin inhibits bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis. Used for Tuberculosis (pulmonary and extrapulmonary), Mycobacterium avium complex (MAC) infection, Leprosy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}